Here, we review the members of the ARF family and their activity regulators and effectors that have been implicated in cancer, and can either function as oncogenes or tumor suppressors and propose possible therapeutic approaches to target ARF family proteins or their effectors, GEFs and GAPs. Here, CDKN2A is linked to cancer.